Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010.
Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010.
复制标题
DOI：
10.1097/aog.0000000000000469
复制
发表时间：
2014-10
影响因子：
7.2
通讯作者：
Sprague BL
中科院分区：
文献类型：
--
作者：
Jewett PI;Gangnon RE;Trentham-Dietz A;Sprague BL
To estimate long term trends in estrogen–progestin prevalence for the U.S. female population by year and age. We integrated data on oral estrogen–progestin use from NHANES 1999–2010 with data from the National Prescription Audit 1970–2003. Distributions of estrogen–progestin by age from NHANES were applied to the prescription data, and calibration and interpolation procedures were used to generate estrogen–progestin prevalence estimates by single year of age and single calendar year for 1970–2010. Estimated prevalence of oral estrogen–progestin was below 0.5% in the 1970s, began to rise in the early 1980s, and almost tripled between 1990 and the late 1990s. The age-adjusted prevalence for women aged 45–64 peaked at 13.5% in 1999, with highest use among 57 year-old women (23.2%). Prevalence of estrogen–progestin use declined dramatically in the early 2000s, with only 2.7% of women aged 45–64 using estrogen–progestin in 2010, which is comparable to prevalence levels in the mid-1980s. The dramatic rise and fall of estrogen–progestin use over the past 40 years provides an illuminating case study of prescription practices before, during, and after the development of evidence regarding benefits and harms.
